← Patent-cliff monitor small molecule CIBINQO ABROCITINIB
Loss of exclusivity January 2036 latest FDA-listed patent expiry
Company Pfizer → See this company's full patent-cliff portfolio Drug detail Brand name CIBINQO Active ingredient ABROCITINIB Strength 200MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval January 2022 Marketing status RX
Listed patents Patent Expires Type 9035074 January 2036 substance, product 9549929 February 2034 use U-3195 9545405 February 2034 substance, product
Regulatory exclusivity Code Expires NCE January 2027 NPP February 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.